Campos Ruiz Amaia, Urtasun Arlegui Leire, Marra-López Valenciano Carlos
Aparato Digestivo, Hospital Universitario de Álava, España.
Aparato Digestivo, Hospital Universitario de Álava.
Rev Esp Enferm Dig. 2016 May;108(5):292-3. doi: 10.17235/reed.2016.4140/2015.
Olmesartan is a therapy used for the management of hypertension available since 2002. A sprue like enteropathy associated with olmesartan has been first described in 2012. Endoscopic and histopathological findings are partial or total villous atrophy, mimicking a Celiac Disease. We explain two cases diagnosed in our hospital. Both patients took more than one year of treatment with olmesartan. In both cases, the biopsy showed duodenal villous atrophy, negative serology for celiac disease and they improved after stopping treatment with olmesartan. Olmesartan associate sprue-like enteropathy should be included in the differential diagnosis of seronegative villous atrophy. After the discontinuation of olmesartan, clinical remission usually occurs in every patients.
奥美沙坦是一种自2002年起用于治疗高血压的药物。2012年首次报道了一种与奥美沙坦相关的口炎性腹泻样小肠病。内镜和组织病理学检查结果为部分或完全绒毛萎缩,类似于乳糜泻。我们解释我院诊断的两例病例。两名患者均接受了一年以上的奥美沙坦治疗。两例病例的活检均显示十二指肠绒毛萎缩,乳糜泻血清学检查阴性,停用奥美沙坦治疗后病情改善。奥美沙坦相关的口炎性腹泻样小肠病应列入血清阴性绒毛萎缩的鉴别诊断中。停用奥美沙坦后,通常每个患者都会出现临床缓解。